This management team clearly can't get the job done. Sure we've heard all the excuses about the FDA, but other companies seem to be able to make progress. SRPT cannot as is evidenced by the latest round of delays.
I wonder what their excuse will be on the next delay.
I never said nothing happened. I said they didn't achieve progress on the primary goal. I'm sure they ran around doing lots of stuff, but they didn't hit the primary objective that was a key element of the valuation of the stock.
Since the stock has lost 2/3 of its value since its peak, so apparently the smart money agrees with me.
After all the pump is gone the shares will settle down to something more reasonable in the mid $20's and average investors like me can get in. No way I'm buying in the $40s.
I'm not sure anybody can give you a definitive answer, but I would take an educated guess that there was an institutional investor who thinks they didn't do a good enough job at CES, or didn't launch the beta on schedule and therefore dumped their shares. In a company this small (micro) they need to be on schedule all the time. Any missteps will be painful.
The stock appears to be coming back some now, probably with the distribution of the Beta kits.
Here is the news release:
Feb 3 (Reuters) - Isis Pharmaceuticals Inc said its experimental diabetes drug was effective in reducing the body weight and blood sugar of patients with type 2 diabetes.
The drug was being tested against a placebo in a mid-stage study comprising 92 patients with type 2 diabetes and uncontrolled blood sugar despite treatment.
Yes the provider can change information about the trial, but when they do, it is entered as a new change record and you can see exactly what changed. So don't be fooled by those trying to mislead you like the people at TheStreet. Each change made is under strict configuration management control that creates a new record with the update, and a differential to show viewers exactly what changed.
Don't let anybody lie and pretend that the submitter can go back and make any changes whatsoever to the original submission. It doesn't work that way and you can even view the change history by clicking on the archival link to see it for yourself.
Now go back and look at the people who are lying about it and check their manipulative motives.
ISIS is clearly under manipulation by short sellers. Whether it will last 6-days or 6-months, only time will tell. It may go right back up or it may go right back to $25/share. It all depends on the manipulators, so be very very careful.
I'm glad I dumped out when I did. As long as this management team is still in place, I fully expect the same lame excuses, the same lack of awareness with the FDA, and the same delays. I do feel bad for patients in need because they are the ones who lose the most.
Shareholders would be wise to demand the resignation and replacement of the whole executive team. Every inept member has to go.
Fully 1/3 of all the shares are shorted, and that is a massive vote of no confidence in the executive team.
It is a novel idea, a camera that records everything in your life. Could be a permanent addition to every police uniform that could cut out a lot of nasty cases, because you can finally see what's really going on during the arrest.
Similarly, parents could verify their kids are doing precisely what they said they'd be doing, which builds the trust etc., so a lot of good can be done with these wearable devices.
That said, they are supposed to have launched the Beta test, but I've not received my Beta unit yet - so I haven't been able to evaluate it against the GoPro or any other device.
Bottom line, it has a lot of potential, but right now, that's all it is - potential.
I probably should have bought a lot more of ANIP at $59.28 but hopefully will be good enough. If they beat the $0.58 EPS consensus then that will bode very well for share price and for the future.
Good news on all fronts.
For the fourth quarter 2014:
- Record net revenues of $21.0 million, an increase of 100% over fourth quarter 2013
- Record adjusted non-GAAP EBITDA of $12.8 million, an increase of 225% over fourth quarter 2013
- Adjusted non-GAAP diluted earnings per share of $1.94, which includes the positive impact of a $16.7 million deferred tax valuation allowance reversal
For the full year ended December 31, 2014:
- Record annual revenues of $56.0 million, an increase of 86% over 2013
- Record adjusted non-GAAP EBITDA of $27.3 million, an increase of 264% over 2013
- Adjusted non-GAAP diluted earnings per share of $2.96, which includes the positive impact of a $16.7 million deferred tax valuation allowance reversal
As the quarterly numbers are fully recognized, the upgrades will start coming in. It was an excellent quarter and this management team continues to perform well.
Yep, I'm dumb, since July 2014 at $30.16/share. I'm stupid like that. Silly me, doubling my investment and all that nonsense.
Yet ANOTHER miss by this management team that continues to demonstrate they need to be replaced. What will their excuse be when yet another delay comes in filing with the FDA?
Today's earnings miss is just the latest in a very long line of missteps that indicate this management team looked good on paper, but isn't cutting it. They simply are NOT performing. Sure they have good excuses, but other companies have FDA filings and FDA approvals. Excuses don't cut it any more.
No more free passes. Replace management!
Think about the market manipulators. They don't issue a BUY rating before they bought the stock, letting you drive up their share prices so they have to pay more for the shares they want.
They issue a "Neutral" rating on it, to try to get a sell off or at least prevent a run up in the share price, so they can buy at reduced levels. Then, once they have picked up 10 or 20 million shares, they upgrade it based on improved conditions or whatever excuse they choose to use.
They can't really put a "SELL" rating on it, because nothing is going to fundamentally change to make it better, since the company is already performing, and nobody would take them seriously. So they go with a "Neutral" rating so they can buy shares cheaper, then upgrade later on any nuance they choose, to make more money.